ClinicalTrials.gg
CompletedNCT03405714Updated May 11, 2022Results posted

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy

A Phase 2 interventional study of Brivaracetam in Epilepsy, sponsored by UCB Biopharma S.P.R.L.. Completed at 17 sites in 7 countries. Open to participants aged 1 Month to 16 Years. Per ClinicalTrials.gov, last updated 2022-05-11.

Sponsored by UCB Biopharma S.P.R.L. (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
1 Month to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
23rd of 34
50 · median 94
Started
2018
the only one that year
Phase 2
6 of 34
none open now
Registered
25th of 34
by date
Lead sponsor
3 of 34
UCB Biopharma S.P.R.L.

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 23rd largest by enrollment, is the only one that started in 2018, is one of 6 in phase 2, and was the 25th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 1 Month to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the pharmacokinetics (PK), safety, and tolerability of brivaracetam (BRV) administered intravenously (iv) in subjects >= 1 month to \< 16 years of age with epilepsy.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Epilepsy
  • Brivaracetam
  • Briviact
  • Open-label
  • pediatric
  • intravenous
04

Who can participate

Ages eligible
1 Month to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female from >= 1 month to \< 16 years of age. For subjects who are \< 1 year from birth and who were preterm infants, the corrected gestational age should be used for this entry requirement
  • Weight >= 3 kg (6.6 lbs)
  • Diagnosis of epilepsy
  • Acceptable candidate for venipuncture and intravenous (iv) infusion
  • Treatment with >=1 anti epileptic drug (AED; including BRV) without a change of dose regimen for at least 7 days prior to Screening
  • No treatment with vagus nerve stimulation (VNS), OR the subject is being treated with VNS and the settings have been constant for >=7 days prior to Screening
  • For female subjects: not of , OR of childbearing potential and not sexually active/negative pregnancy test, OR of childbearing potential and sexually active/negative pregnancy test/uses medically acceptable methods

Exclusion criteria

Exclusion Criteria:

  • Subject has previously received iv Brivaracetam (BRV) in this study
  • Subject is being treated with BRV at a dose >5mg/kg/day (rounded) or >200mg/day for subjects with body weights >40kg
  • Subject requires or is likely to require a change in concomitant antiepileptic drug(s) (AED[s]), dose of concomitant AED(s), or formulation of AED(s) during the 7 days prior to the intravenous (iv) pharmacokinetic (PK) Period
  • Subject is likely, in the opinion of the Investigator, to require rescue medication during the Initiating Oral BRV (IOB) Treatment or iv PK Periods
  • Subject has experienced generalized convulsive status epilepticus in the 28 days prior to Screening or during the Screening Period
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Brivaracetam

    Brivaracetam will be administered to various age-based cohorts. Cohort 1: Subjects \>=12 to \<16 years; Cohort 2: Subjects \>=6 to \<12 years; Cohort 3: Subjects \>=2 to \<6 years; Cohort 4: Subjects 1 month to \<2 years. Enrollment will be sequential by descending age beginning with Cohort 1. For each cohort, the first half will receive a 15-minute iv infusion. The Data Monitoring Committee (DMC) will then review safety and, as available, PK data to make the following recommendations: the progression of the current cohort (up to 2-minute iv bolus infusion) and progression to initiate enrollment in the preceding cohort.

    Drug: Brivaracetam

Interventions

  • * Pharmaceutical form: Solution for iv injection * Route of administration: intravenous use * Concentration: 10 mg/ml

    Also known as: Briviact

06

What researchers measure

Primary outcomes

  1. Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 3 (Day 1 of IV PK period)

  2. Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)

  3. Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)

  4. Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 4 (Day 2 of IV PK period)

  5. Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)

  6. Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)

  7. Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 5 (Day 2 of IV PK period)

  8. Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)

  9. Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)

  10. Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3 by Infusion Duration - 15 Minutes

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 3 (Day 1 of IV PK period)

  11. Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3 by Infusion Duration- 15 Minutes

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)

  12. Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3 by Infusion Duration- 15 Minutes

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)

  13. Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4 by Infusion Duration- 15 Minutes

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 4 (Day 2 of IV PK period)

  14. Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4 by Infusion Duration- 15 Minutes

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)

  15. Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4 by Infusion Duration- 15 Minutes

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)

  16. Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5 by Infusion Duration- 15 Minutes

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 5 (Day 2 of IV PK period)

  17. Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5 by Infusion Duration- 15 Minutes

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)

  18. Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5 by Infusion Duration- 15 Minutes

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)

  19. Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3 by Infusion Duration- Bolus

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 3 (Day 1 of IV PK period)

  20. Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3 by Infusion Duration- Bolus

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)

  21. Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3 by Infusion Duration- Bolus

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)

  22. Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4 by Infusion Duration- Bolus

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: At <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 4 (Day 2 of IV PK period)

  23. Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4 by Infusion Duration- Bolus

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: At 15 minutes post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)

  24. Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4 by Infusion Duration- Bolus

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: At 3 hours post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)

  25. Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5 by Infusion Duration- Bolus

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 5 (Day 2 of IV PK period)

  26. Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5 by Infusion Duration- Bolus

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)

  27. Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5 by Infusion Duration- Bolus

    Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

    Time frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)

  28. Number of Participants With Adverse Events (AEs)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.

    Time frame: From Screening until last visit (up to Day 68)

  29. Number of Participant Withdrawals Due to Adverse Events

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.

    Time frame: From Screening until last visit (up to Day 68)

07

Results

Posted Nov 26, 2021

Participant flow

The study started to enroll participants in June 2018 and concluded in November 2020.

Participant flow — Overall Study
MilestoneAge Cohort: >=12 to <16 YearsAge Cohort: >=6 to <12 YearsAge Cohort: >=2 to <6 YearsAge Cohort: >=1 Month to <2 Years
Started12121313
Completed12121313
Not completed0000

Outcome measures

PrimaryPlasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 3 (Day 1 of IV PK period)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3
nanograms per milliliter (ng/mL)Age Cohort: >=12 to <16 Years (PK-PPS)Age Cohort: >=6 to <12 Years (PK-PPS)Age Cohort: >=2 to <6 Years (PK-PPS)Age Cohort : >=1 Month to <2 Years (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3149.0 (27.6 to 805.1)NA (NA to NA)NA (NA to NA)310.6 (92.5 to 1042.7)
PrimaryPlasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3
ng/mLAge Cohort: >=12 to <16 Years (PK-PPS)Age Cohort: >=6 to <12 Years (PK-PPS)Age Cohort: >=2 to <6 Years (PK-PPS)Age Cohort : >=1 Month to <2 Years (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 31844.6 (1110.4 to 3064.3)2058.8 (1726.4 to 2455.2)1774.9 (1087.4 to 2897.1)1566.6 (973.1 to 2522.2)
PrimaryPlasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3
ng/mLAge Cohort: >=12 to <16 Years (PK-PPS)Age Cohort: >=6 to <12 Years (PK-PPS)Age Cohort: >=2 to <6 Years (PK-PPS)Age Cohort : >=1 Month to <2 Years (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 31260.6 (962.6 to 1650.8)1189.5 (1005.5 to 1407.1)1225.3 (676.8 to 2218.6)1341.7 (657.9 to 2735.9)
PrimaryPlasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 4 (Day 2 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4
ng/mLAge Cohort: >=12 to <16 Years (PK-PPS)Age Cohort: >=6 to <12 Years (PK-PPS)Age Cohort: >=2 to <6 Years (PK-PPS)Age Cohort : >=1 Month to <2 Years (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4—290.5 (101.2 to 834.0)——
PrimaryPlasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4
ng/mLAge Cohort: >=12 to <16 Years (PK-PPS)Age Cohort: >=6 to <12 Years (PK-PPS)Age Cohort: >=2 to <6 Years (PK-PPS)Age Cohort : >=1 Month to <2 Years (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4—2084.3 (681.2 to 6377.0)——
PrimaryPlasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4
ng/mLAge Cohort: >=12 to <16 Years (PK-PPS)Age Cohort: >=6 to <12 Years (PK-PPS)Age Cohort: >=2 to <6 Years (PK-PPS)Age Cohort : >=1 Month to <2 Years (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4—1149.8 (613.1 to 2156.4)——
PrimaryPlasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 5 (Day 2 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5
ng/mLAge Cohort: >=12 to <16 Years (PK-PPS)Age Cohort: >=6 to <12 Years (PK-PPS)Age Cohort: >=2 to <6 Years (PK-PPS)Age Cohort : >=1 Month to <2 Years (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5—466.0 (NA to NA)204.5 (0.1 to 383063.7)482.9 (4.8 to 48506.1)
PrimaryPlasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5
ng/mLAge Cohort: >=12 to <16 Years (PK-PPS)Age Cohort: >=6 to <12 Years (PK-PPS)Age Cohort: >=2 to <6 Years (PK-PPS)Age Cohort : >=1 Month to <2 Years (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5—2890.0 (NA to NA)1948.8 (690.8 to 5497.7)2072.4 (743.2 to 5778.8)
PrimaryPlasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5
ng/mLAge Cohort: >=12 to <16 Years (PK-PPS)Age Cohort: >=6 to <12 Years (PK-PPS)Age Cohort: >=2 to <6 Years (PK-PPS)Age Cohort : >=1 Month to <2 Years (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5—1820 (NA to NA)1203.5 (147.1 to 9847.1)727.4 (144.9 to 3652.9)
PrimaryPlasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3 by Infusion Duration - 15 Minutes

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 3 (Day 1 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3 by Infusion Duration - 15 Minutes
ng/mL15-minute Infusion (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3 by Infusion Duration - 15 MinutesNA (NA to NA)
PrimaryPlasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3 by Infusion Duration- 15 Minutes

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3 by Infusion Duration- 15 Minutes
ng/mL15-minute Infusion (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3 by Infusion Duration- 15 Minutes1903.0 (1474.9 to 2455.4)
PrimaryPlasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3 by Infusion Duration- 15 Minutes

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3 by Infusion Duration- 15 Minutes
ng/mL15-minute Infusion (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3 by Infusion Duration- 15 Minutes1130.3 (882.1 to 1448.3)
PrimaryPlasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4 by Infusion Duration- 15 Minutes

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 4 (Day 2 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4 by Infusion Duration- 15 Minutes
ng/mL15-minute Infusion (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4 by Infusion Duration- 15 Minutes290.5 (101.2 to 834.0)
PrimaryPlasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4 by Infusion Duration- 15 Minutes

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4 by Infusion Duration- 15 Minutes
ng/mL15-minute Infusion (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4 by Infusion Duration- 15 Minutes2084.3 (681.2 to 6377.0)
PrimaryPlasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4 by Infusion Duration- 15 Minutes

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4 by Infusion Duration- 15 Minutes
ng/mL15-minute Infusion (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4 by Infusion Duration- 15 Minutes1149.8 (613.1 to 2156.4)
PrimaryPlasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5 by Infusion Duration- 15 Minutes

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 5 (Day 2 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5 by Infusion Duration- 15 Minutes
ng/mL15-minute Infusion (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5 by Infusion Duration- 15 Minutes776.0 (51.9 to 11611.3)
PrimaryPlasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5 by Infusion Duration- 15 Minutes

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5 by Infusion Duration- 15 Minutes
ng/mL15-minute Infusion (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5 by Infusion Duration- 15 Minutes2697.8 (1911.1 to 3808.3)
PrimaryPlasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5 by Infusion Duration- 15 Minutes

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5 by Infusion Duration- 15 Minutes
ng/mL15-minute Infusion (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5 by Infusion Duration- 15 Minutes1030.0 (376.1 to 2820.9)
PrimaryPlasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3 by Infusion Duration- Bolus

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 3 (Day 1 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3 by Infusion Duration- Bolus
ng/mLBolus (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3 by Infusion Duration- Bolus120.5 (44.7 to 325.2)
PrimaryPlasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3 by Infusion Duration- Bolus

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3 by Infusion Duration- Bolus
ng/mLBolus (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3 by Infusion Duration- Bolus1704.8 (1237.5 to 2348.4)
PrimaryPlasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3 by Infusion Duration- Bolus

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3 by Infusion Duration- Bolus
ng/mLBolus (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3 by Infusion Duration- Bolus1383.9 (989.3 to 1935.8)
PrimaryPlasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4 by Infusion Duration- Bolus

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
At <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 4 (Day 2 of IV PK period)

No measurements were reported for this outcome.

PrimaryPlasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4 by Infusion Duration- Bolus

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
At 15 minutes post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)

No measurements were reported for this outcome.

PrimaryPlasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4 by Infusion Duration- Bolus

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
At 3 hours post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)

No measurements were reported for this outcome.

PrimaryPlasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5 by Infusion Duration- Bolus

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 5 (Day 2 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5 by Infusion Duration- Bolus
ng/mLBolus (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5 by Infusion Duration- Bolus167.5 (9.6 to 2932.2)
PrimaryPlasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5 by Infusion Duration- Bolus

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5 by Infusion Duration- Bolus
ng/mLBolus (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5 by Infusion Duration- Bolus1531.8 (837.3 to 2802.2)
PrimaryPlasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5 by Infusion Duration- Bolus

Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.

Time frame:
Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5 by Infusion Duration- Bolus
ng/mLBolus (PK-PPS)
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5 by Infusion Duration- Bolus949.5 (2.8 to 316987.2)
PrimaryNumber of Participants With Adverse Events (AEs)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.

Time frame:
From Screening until last visit (up to Day 68)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsAge Cohort: >=12 to <16 Years (SS-iv)Age Cohort: >=6 to <12 Years (SS-iv)Age Cohort: >=2 to <6 Years (SS-iv)Age Cohort: >=1 Month to <2 Years (SS-iv)
Number of Participants With Adverse Events (AEs)3472
PrimaryNumber of Participant Withdrawals Due to Adverse Events

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.

Time frame:
From Screening until last visit (up to Day 68)
Reported as:
Count of participants · Participants
Number of Participant Withdrawals Due to Adverse Events
ParticipantsAge Cohort: >=12 to <16 Years (SS-iv)Age Cohort: >=6 to <12 Years (SS-iv)Age Cohort: >=2 to <6 Years (SS-iv)Age Cohort: >=1 Month to <2 Years (SS-iv)
Number of Participant Withdrawals Due to Adverse Events0000

Adverse events

Collected over From Screening until last visit (up to Day 68). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Age Cohort: >=12 to <16 Years (SS-iv)0/12 (0%)0/12 (0%)3/12 (25%)
Age Cohort: >=6 to <12 Years (SS-iv)0/12 (0%)0/12 (0%)4/12 (33.3%)
Age Cohort: >=2 to <6 Years (SS-iv)0/13 (0%)0/13 (0%)7/13 (53.8%)
Age Cohort: >=1 Month to <2 Years (SS-iv)0/13 (0%)1/13 (7.7%)2/13 (15.4%)
Most frequent serious events
Most frequent serious events
EventAge Cohort: >=12 to <16 Years (SS-iv)Age Cohort: >=6 to <12 Years (SS-iv)Age Cohort: >=2 to <6 Years (SS-iv)Age Cohort: >=1 Month to <2 Years (SS-iv)
CoughRespiratory, thoracic and mediastinal disorders0/120/120/131/13
Most frequent other events
Showing 10 of 15
Most frequent other events
EventAge Cohort: >=12 to <16 Years (SS-iv)Age Cohort: >=6 to <12 Years (SS-iv)Age Cohort: >=2 to <6 Years (SS-iv)Age Cohort: >=1 Month to <2 Years (SS-iv)
DizzinessNervous system disorders2/120/120/130/13
PyrexiaGeneral disorders0/120/122/130/13
Ear infectionInfections and infestations0/120/122/130/13
SomnolenceNervous system disorders0/120/122/131/13
VomitingGastrointestinal disorders0/121/120/130/13
FatigueGeneral disorders0/121/121/130/13
PharyngitisInfections and infestations1/120/120/130/13
InsomniaPsychiatric disorders0/121/120/130/13
PruritusSkin and subcutaneous tissue disorders0/121/120/130/13
RashSkin and subcutaneous tissue disorders0/121/121/130/13

Baseline characteristics

Baseline Characteristics refer to SS-iv, which included study participants who received at least 1 dose of iv BRV.

Age, Categorical
Age, Categorical(Participants)Age Cohort: >=12 to <16 YearsAge Cohort: >=6 to <12 YearsAge Cohort: >=2 to <6 YearsAge Cohort: >=1 Month to <2 YearsTotal Title
<=18 years1212131350
Between 18 and 65 years00000
>=65 years00000
Age, Continuous
Age, Continuous(years)Age Cohort: >=12 to <16 YearsAge Cohort: >=6 to <12 YearsAge Cohort: >=2 to <6 YearsAge Cohort: >=1 Month to <2 YearsTotal Title
Mean13.08 ± 1.168.33 ± 1.613.85 ± 0.990.95 ± 0.596.39 ± 4.76
Sex: Female, Male
Sex: Female, Male(Participants)Age Cohort: >=12 to <16 YearsAge Cohort: >=6 to <12 YearsAge Cohort: >=2 to <6 YearsAge Cohort: >=1 Month to <2 YearsTotal Title
Female685524
Male648826
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Age Cohort: >=12 to <16 YearsAge Cohort: >=6 to <12 YearsAge Cohort: >=2 to <6 YearsAge Cohort: >=1 Month to <2 YearsTotal Title
American Indian/Alaskan Native00022
Black10001
White1112131147
08

Study locations

17 sites
  • Ep0065 252
    Bronx, New York 10467, United States
  • Ep0065 237
    Durham, North Carolina 27710, United States
  • Ep0065 502
    Hradec Králové, Czechia
  • Ep0065 240
    Praha 4, Czechia
  • Ep0065 242
    Berlin, Germany
  • Ep0065 254
    Bielefeld, Germany
  • Ep0065 210
    Budapest, Hungary
  • Ep0065 224
    Budapest, Hungary
  • Ep0065 247
    Budapest, Hungary
  • Ep0065 222
    Debrecen, Hungary
  • Ep0065 232
    Miskolc, Hungary
  • Ep0065 264
    Milan, Italy
  • Ep0065 238
    Pavia, Italy
  • Ep0065 239
    Pavia, Italy
  • Ep0065 230
    Roma, Italy
  • Ep0065 223
    Aguas Calientes, Mexico
  • Ep0065 248
    Sevilla, Spain
09

References and documents

Publications

  • Farkas MK, Kang H, Fogarasi A, Bozorg A, James GD, Krauwinkel W, Morita D, Will E, Elshoff JP. Pharmacokinetics, safety, and tolerability of intravenous brivaracetam in pediatric patients with epilepsy: An open-label trial. Epilepsia. 2022 Apr;63(4):855-864. doi: 10.1111/epi.17187. Epub 2022 Feb 23. PubMed 35196395 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Nov 2020, 29 months.

Results were first posted in Nov 2021, 1 year after primary completion.

Of 45 industry-sponsored phase 2 interventional studies under Epilepsy, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 29 months is above that.

Counting every sponsor, half of 66 studies reached it within 23 months; a quarter within 14 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2018
First posted
Jan 23, 2018
StartActual
Jun 1, 2018
Primary completionActual
Nov 4, 2020
CompletionActual
Nov 4, 2020
Results first posted
Nov 26, 2021
Last update
May 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03405714
Responsible party
Sponsor
First posted
Jan 23, 2018
Start date
Jun 1, 2018
Primary completion
Nov 4, 2020
Completion
Nov 4, 2020
Results posted
Nov 26, 2021
Last update
May 11, 2022

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion